The clinical potential of oligonucleotide therapeutics against pancreatic cancer

Kazuki Takakura, Atsushi Kawamura, Yuichi Torisu, Shigeo Koido, Naohisa Yahagi, Masayuki Saruta

Research output: Contribution to journalReview articlepeer-review

31 Citations (Scopus)


Although many diagnostic and therapeutic modalities for pancreatic cancer have been proposed, an urgent need for improved therapeutic strategies remains. Oligonucleotide therapeutics, such as those based on antisense RNAs, small interfering RNA (siRNA), microRNA (miRNA), aptamers, and decoys, are promising agents against pancreatic cancer, because they can identify a specific mRNA fragment of a given sequence or protein, and interfere with gene expression as molecular-targeted agents. Within the past 25 years, the diversity and feasibility of these drugs as diagnostic or therapeutic tools have dramatically increased. Several clinical and preclinical studies of oligonucleotides have been conducted for patients with pancreatic cancer. To support the discovery of effective diagnostic or therapeutic options using oligonucleotide-based strategies, in the absence of satisfactory therapies for long-term survival and the increasing trend of diseases, we summarize the current clinical trials of oligonucleotide therapeutics for pancreatic cancer patients, with underlying preclinical and scientific data, and focus on the possibility of oligonucleotides for targeting pancreatic cancer in clinical implications.

Original languageEnglish
Article number3331
JournalInternational journal of molecular sciences
Issue number13
Publication statusPublished - 2019 Jul 1


  • Antisense
  • Aptamer
  • Decoy
  • Oligonucleotide therapeutics
  • Pancreatic cancer
  • RNA interference

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'The clinical potential of oligonucleotide therapeutics against pancreatic cancer'. Together they form a unique fingerprint.

Cite this